



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 82533

Title: Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06272301

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Spain

Manuscript submission date: 2022-12-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-12-22 02:51

Reviewer performed review: 2022-12-25 12:37

Review time: 3 Days and 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

In this mini review, the authors focus on advances in next-generation sequencing in B-cell lymphoma diagnosis, prognosis, and treatment options. This article is comprehensive in content, logical and appropriate in language, which meets the requirements of this journal. But there are still some points worth paying attention to: 1. I see that the author mentioned B-cell lymphoma in the title, but the article is mainly about DLBCL and FL. Although the latter two account for a larger proportion of B-cell lymphomas, they are not substitutes. Hope the author in the article appropriate explanation or choice. 2. The author used a general sentence at the end of the introduction. I think that as a review article, the introduction should properly explain the following parts of the article and briefly explain why it was written. In this way, readers can quickly understand the author's intention and have a more systematic understanding of the full text. 3. The authors systematically explain in detail the value of NGS in detecting genetic abnormalities in the diagnosis, treatment and prognosis of B-cell lymphoma. As far as I know, molecular biology and cytogenetics are well established in the diagnosis and treatment of hematological tumors. Does this make some of the ideas in this article seem less innovative? It is suggested that the authors should further consider whether relevant methods have other application values such as early diagnosis and prevention of tumors. 4. I am puzzled by the author's suggestion that molecular detection can be applied to CAR-T therapy. The only mention in the paper that molecular technology can be applied to monitor the number of CAR-T cells in peripheral blood does not seem to be considered a progress, since qPCR has long been a traditional means of laboratory detection. CAR-T cells can also be detected by



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

immunoassay. I hope the author can give a more detailed explanation. 5. According to the citation format requirements of the World Journal of Clinical Oncology, the first author's name seems to need to be bold and the name of the cited article needs to be italicized. I hope the author carefully check the full text against the article format requirements. Finally, I noticed that the literature cited by the author is relatively old, so I hope the author can quote more relevant articles in the recent five years to ensure the latest content.



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 82533

Title: Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04729411

Position: Peer Reviewer

Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: Iran

Author's Country/Territory: Spain

Manuscript submission date: 2022-12-21

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-03-17 14:00

Reviewer performed review: 2023-03-17 14:14

Review time: 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



Baishideng Publishing Group

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear Editorial Team, Thank you for sharing this manuscript with me. This mini review is very informative and useful. It is written good, but I found one abbreviated word, which is unfamiliar, IHQ was used for immunnohistochemistry instead of IHC. Otherwise it is acceptable.